+44-1518081136Opinion Article - Journal of Clinical Research and Pharmacy (2025) Volume 8, Issue 3
Optimizing drug bioavailability: Multi-faceted strategies
Michael Adams*
Department of Clinical Pharmacy, University of California, San Francisco, USA
- *Corresponding Author:
- Michael Adams
Department of Clinical Pharmacy
University of California, San Francisco, USA.
E-mail: michael.adams@ucsf.edu
Received : 01-Aug-2025, Manuscript No. aajcrp-187; Editor assigned : 05-Aug-2025, PreQC No. aajcrp-187(PQ); Reviewed : 25-Aug-2025, QC No aajcrp-187; Revised : 03-Sep-2025, Manuscript No. aajcrp-187(R); Published : 12-Sep-2025 , DOI : 10.35841/aajcrp.7.3.187
Citation: Adams M. Optimizing drug bioavailability: Multi-faceted strategies. aajcrp. 2025;08(03):187.
Introduction
Pharmaceutical science consistently seeks innovative strategies to enhance the oral bioavailability of drugs, particularly those with poor water solubility. These critical approaches include particle size reduction, solid dispersions, lipid-based formulations, and prodrugs. Each method works to improve drug absorption and systemic exposure, proving indispensable for rendering promising drug candidates clinically viable [1].
Building on these foundational techniques, nanocarrier systems are rapidly advancing drug delivery, especially in boosting oral bioavailability. Nanocarriers like nanoparticles, liposomes, and micelles leverage unique mechanisms to improve drug solubility, stability, and permeability across biological barriers. This innovation is crucial for overcoming the inherent limitations of traditional drug formulations, thereby paving the way for more effective oral therapies [2].
A comprehensive understanding of the multifaceted factors that influence oral drug bioavailability is paramount. These factors span from a drug's intrinsic physicochemical properties to complex physiological barriers within the body. Addressing these challenges is fundamental to successful drug development, and a clear framework for researchers and developers is essential when grappling with bioavailability issues [3].
Beyond the drug itself, the food matrix plays a significant role in modulating the bioavailability of various active compounds, including vital nutrients and phytochemicals. Complex interactions between food components and these active compounds can profoundly influence their release, digestion, absorption, and subsequent metabolism. Recognizing these intricate relationships is key to optimizing dietary intake and developing functional foods designed for enhanced health benefits [4].
In the realm of natural products, phytosome technology emerges as an innovative method specifically designed to improve the bioavailability of herbal extracts, which often face challenges due to poor absorption. This technology involves encapsulating plant-derived compounds within phospholipid complexes, effectively enhancing their solubility and permeability across biological membranes. This leads to improved therapeutic outcomes and represents a promising avenue for increasing the efficacy of natural products in various health applications [5].
Regulatory oversight in drug development relies heavily on bioequivalence studies. These studies are fundamental for the approval of generic drugs and new drug formulations alike. They encompass meticulous clinical design, rigorous statistical analysis, and strict adherence to regulatory considerations. Such evaluations are critical to ensure that different drug products deliver the same therapeutic effect, thereby upholding drug quality and patient safety standards [6].
A unique set of challenges arises when aiming for adequate oral bioavailability in pediatric patient populations, largely due to their continuously developing physiology. To address this, specialized formulation strategies are required, including taste masking, precise dose accuracy, and modified release systems tailored specifically for children. Emphasizing age-appropriate formulations is crucial for ensuring both effective and safe drug administration for this vulnerable group [7].
The pharmaceutical development pipeline is further streamlined by the critical application of In Vitro-In Vivo Correlation (IVIVC). IVIVC models are instrumental in predicting in vivo drug performance based on in vitro dissolution data. This capability aids significantly in optimizing formulations, maintaining stringent quality control, and reducing the necessity for extensive clinical trials. Ultimately, IVIVC's utility in establishing biowaivers and bridging studies helps accelerate drug product approval processes [8].
Bridging traditional knowledge with modern pharmaceutical science, efforts are underway to enhance the oral bioavailability of active compounds found in Traditional Chinese Medicine (TCM). These compounds often face challenges related to poor solubility and extensive metabolism. Modern pharmaceutical techniques, such as nanotechnology, prodrug design, and co-crystallization, are being applied to significantly improve the therapeutic efficacy of TCM formulas, underscoring a vital convergence of ancient wisdom and contemporary science [9].
Finally, lipid-based formulations (LBFs) stand out as a highly effective and versatile strategy for significantly boosting the oral bioavailability of drugs characterized by poor water solubility. LBFs, including sophisticated self-emulsifying drug delivery systems, work by improving drug solubilization, offering protection against degradation, and enhancing lymphatic transport. This latter mechanism is particularly beneficial as it helps bypass hepatic first-pass metabolism, a common obstacle in drug delivery, thus highlighting the broad success of LBFs in pharmaceutical development [10].
Conclusion
Addressing challenges in oral drug bioavailability is a central theme in pharmaceutical science, with various innovative strategies developed to improve drug absorption and systemic exposure. For drugs with poor water solubility, approaches like particle size reduction, solid dispersions, lipid-based formulations, and prodrugs are crucial to enhance their viability for clinical use. Nanocarrier systems, including nanoparticles, liposomes, and micelles, further transform drug delivery by improving solubility, stability, and permeability across biological barriers, overcoming traditional formulation limitations. The complex factors influencing drug bioavailability, ranging from physicochemical properties to physiological barriers, necessitate a deep understanding for successful drug development. Beyond drug properties, external factors such as the food matrix significantly impact the bioavailability of active compounds, including nutrients and phytochemicals, by influencing their release, digestion, absorption, and metabolism. This highlights the importance of optimizing dietary intake and developing functional foods. Specialized technologies, like phytosome technology, offer a novel method to improve the bioavailability of herbal extracts by encapsulating plant-derived compounds in phospholipid complexes, thereby enhancing their efficacy in natural health applications. Furthermore, the field grapples with specific population needs, such as pediatric patients, whose developing physiology presents unique challenges to oral bioavailability. Tailored formulation strategies, including taste masking and modified release systems, are essential for safe and effective drug administration in children. The integration of traditional knowledge, like that found in Traditional Chinese Medicine (TCM), with advanced pharmaceutical techniques such as nanotechnology and prodrug design, also offers pathways to improve therapeutic efficacy. Regulatory and developmental tools, including bioequivalence studies for generic drug approval and In Vitro-In Vivo Correlation (IVIVC) models, are vital for streamlining development, ensuring drug quality, and accelerating product approval. Overall, these efforts underscore a multi-faceted approach to enhancing drug bioavailability, covering formulation science, patient-specific considerations, natural product enhancement, and regulatory frameworks, all aimed at optimizing therapeutic outcomes and patient safety.
References
- Yu Q, Zhen L, Xue Z. Strategies for improving oral bioavailability of poorly water-soluble drugs. Drug Deliv. 2021;28(1):1985-2007.
- Tao Z, Jie W, Zi S. Recent advances in nanocarrier-based drug delivery systems for improving oral bioavailability. Int J Pharm. 2020;574(None specified):118934.
- Rakesh K, Manthini A, Karpagam P. Oral bioavailability of pharmaceutical products: a critical overview. Drug Deliv Transl Res. 2023;13(1):3-28.
- Soumaya Z, Michel L, Salwa K. Impact of food matrix on the bioavailability of active compounds: A review. Compr Rev Food Sci Food Saf. 2020;19(5):2527-2549.
- Dhananjay RT, Vishal MC, Vikas MK. Phytosome technology: A novel approach to enhance the bioavailability of herbal extracts. Phytomedicine. 2022;106(None specified):154432.
- Mei-Ling C, Vinod S, Rajesh P. Bioequivalence studies: Clinical and regulatory perspectives. Clin Pharmacol Ther. 2020;108(2):239-247.
- Harmeet G, Vartouhi K, Helen KB. Formulation strategies for improved oral bioavailability in paediatric populations. Int J Pharm. 2020;579(None specified):119156.
- Vikas K, Harjot W, Khushboo K. Applications of in vitro-in vivo correlation (IVIVC) in pharmaceutical development. Eur J Drug Metab Pharmacokinet. 2020;45(6):687-700.
- Hongyu Y, Guiyuan W, Jie S. Strategies for improving the oral bioavailability of traditional Chinese medicine components: A review. J Ethnopharmacol. 2021;264(None specified):113337.
- Santosh P, Suvarna S, Ankita S. Lipid-based formulations as a versatile platform for enhancing oral bioavailability of poorly water-soluble drugs. Future J Pharm Sci. 2022;8(1):63.
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref